Lipopolysaccharide Adsorption At Septic Shock

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

58 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-03-23

Study Completion Date

2022-08-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Sepsis is a global healthcare burden sepsis, it reaches 20-30 million cases annually (WHO data). Numerous studies have shown that extracorporeal hemoperfusion therapies that eliminate endotoxin and\\or excess of cytokines improve treatment outcomes in patients with septic shock. The main purpose of the study is to obtain new data on the efficacy and safety of the Efferon LPS device in extracorporeal therapy in patients with abdominal sepsis complicated by septic shock.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efferon LPS Hemoperfusion for Treatment of Patients With Septic Shock

NCT04884854

Septic Shock

COMPLETED

Combined Hemoperfusion and Therapeutic Plasma Exchange for Treatment of Patients With Septic Shock

NCT06404424

Sepsis Septic Shock

COMPLETED

Lipopolysaccharide Adsorption (Efferon LPS NEO) in Children With Sepsis

NCT05707494

Sepsis Septic Shock

COMPLETED NA

Selective Lipopolysaccharide Hemosorption in Maternal Sepsis

NCT05711901

Maternal sepsIs

COMPLETED NA

Clearance of Antibacterial Agents During Hemoperfusion in Patients With Sepsis

NCT06602245

Sepsis Septic Shock

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Sepsis is a global healthcare burden sepsis, it reaches 20-30 million cases annually (WHO data). A two-stage trial by Rudnov et al. using one-day data from 62 centres in 29 subjects of the Russian Federation showed that one third of the patients admitted to the ICU were patients with infection, one fifth of them developed septic shock, the proportion of hospital sepsis was 46.6%, and fatal outcome occurred in 30.4% of patients with infection. Despite apparent advances in intensive care, the prognosis of patients with endotoxaemia and septic shock remains poor.

Extracorporeal removal of toxic substances from the bloodstream by adsorbing them onto a porous material may provide clear clinical benefits. Extracorporeal blood adsorption method can be a good complement or substitute for the classical methods of haemofiltration and haemodialysis if the diffusion or convection of toxic substances through the membrane is not efficient enough. Since the method was first proposed by Muirhead and Reid in 1948, it has developed considerably.

Endotoxin (lipopolysaccharide), one of the most potent mediators of sepsis, is found in high concentrations in about 50% of patients with septic shock. The use of extracorporeal sorption techniques that eliminate endotoxin has been shown in numerous trials to improve outcomes in patients with septic shock.

Efferon LPS (Efferon JSC, Moscow, Russia) is a single-use therapeutic device for extracorporeal blood purification using direct hemoperfusion. Detoxification is carried out by selective adsorption of lipopolysaccharides (bacterial endotoxins) and non-selective removal of cytokines by internal porous structure. It is a cylindrical polycarbonate casing filled with spherical granules of LPS-selective polymeric adsorbent mesoporous beads and isotonic sodium chloride solution. The device is registered in Russia as a medical device RZN 2019/8886.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Septic Shock

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

A multicentre randomised clinical trial evaluating the efficacy and safety of the Efferon LPS device in extracorporeal hemoperfusion in patients with abdominal sepsis complicated with septic shock.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Basic therapy + Efferon LPS

Basic therapy is the institution's routine practice for treating patients with septic shock against a background of abdominal sepsis plus extracorporeal hemoperfusion therapy (Efferon LPS)

Group Type EXPERIMENTAL

Efferon LPS hemoperfusion

Intervention Type DEVICE

Hemoperfusion using continuous extracorporeal LPS adsorption with Efferon LPS therapeutic device during a period of 24h immediately following admission to the intensive care unit

Baseline therapy

Basic therapy is the institution's routine practice for treating patients with septic shock against a background of abdominal sepsis.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Efferon LPS hemoperfusion

Hemoperfusion using continuous extracorporeal LPS adsorption with Efferon LPS therapeutic device during a period of 24h immediately following admission to the intensive care unit

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

extracorporeal blood adsorption

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥18 years
* Established diagnosis of Gram-negative septic shock according to SEPSIS-3 criteria
* The immediate post-operative period (no more than 24 hours after surgery)
* Hypotension requiring vasopressor support: the need for at least one of the vasopressors listed below at the dose listed below for at least 2 hours continuously and not more than 12 hours.

* Norepinephrine\> 0.05 µg/kg/min
* Dopamine\> 10 µg/kg/min
* Phenylephrine\> 0.4 µg/kg/min
* Adrenaline \> 0.05 µg/kg/min
* Vasopressin\> 0.03 units/min Vasopressin (any dose) in combination with another vasopressor listed above
* The patient must have received intravenous infusion therapy of at least 30 ml/kg administered within 24 hours of inclusion.
* The patient's condition allows therapy with the Efferon LPS device for at least 4 hours.

Exclusion Criteria

Lack of adequate antimicrobial chemotherapy

* Identifying the criteria for non-inclusion;
* A patient may voluntarily withdraw from a trial at any time after giving informed consent and before the trial is completed. The investigator may also withdraw a participant from the trial at any time at his or her discretion and for any of the following reasons:
* Reasons for a participant's withdrawal from the trial will be recorded and may include, amongst others, the following
* Withdrawal of consent to participate in the trial by the participant.
* The development of an adverse event, including a serious one; individual intolerance to the investigational product, hypersensitivity to the components of the product due to which further participation in the trial is not possible.
* Continued participation in the trial is not, in the researcher's opinion, in the participant's health interests.
* The presence of deviations from the plan which, in the opinion of the Sponsor and Investigator, require the withdrawal of the participant from the trial.
* A positive pregnancy test result at any time during the test.
* When any participant withdraws from a trial, the reason for the withdrawal should be documented.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No